Safety, immunogenicity and protective effectiveness of heterologous boost with a recombinant COVID-19 vaccine (Sf9 cells) in adult recipients of inactivated vaccines

Safety, immunogenicity and protective effectiveness of heterologous boost with a recombinant COVID-19 vaccine (Sf9 cells) in adult recipients of inactivated vaccines

Abstract Vaccines have proven effective in protecting populations against COVID-19, including the recombinant COVID-19 vaccine (Sf9 cells), the first approved recombinant protein vaccine in China. In this positive-controlled trial with 85 adult participants (Sf9 cells group: n = 44; CoronaVac group:...

Full description

Bibliographic Details
Main Authors: Wenxin Luo, Jiadi Gan, Zhu Luo, Shuangqing Li, Zhoufeng Wang, Jiaxuan Wu, Huohuo Zhang, Jinghong Xian, Ruixin Cheng, Xiumei Tang, Yi Liu, Ling Yang, Qianqian Mou, Xue Zhang, Yi Chen, Weiwen Wang, Yantong Wang, Lin Bai, Xuan Wei, Rui Zhang, Lan Yang, Yaxin Chen, Li Yang, Yalun Li, Dan Liu, Weimin Li, Lei Chen
Format: Article
Language:English
Published: Nature Publishing Group 2024-02-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-024-01751-1

Internet

https://doi.org/10.1038/s41392-024-01751-1

Similar Items